Note: This article is for educational use only and is based on current U.S. prescribing and patient-safety information from reputable medical sources, including FDA-approved labeling, DailyMed, NIH HIVinfo, MedlinePlus, CDC, Cleveland Clinic, Mayo Clinic, Drugs.com, and manufacturer professional information. It is not a substitute for care from an HIV specialist, pharmacist, or healthcare provider.
What Is Delstrigo?
Delstrigo is a once-daily prescription HIV-1 medication that combines three antiretroviral medicines in one tablet: doravirine, lamivudine, and tenofovir disoproxil fumarate. In plain English, it is a complete HIV treatment regimen packed into one yellow pill, which is much easier to remember than a tiny pharmacy parade marching across your nightstand.
Delstrigo is used to treat human immunodeficiency virus type 1, commonly called HIV-1. HIV-1 is the virus that can lead to AIDS if it is not treated. Delstrigo does not cure HIV or AIDS, but when taken exactly as prescribed, it can lower the amount of HIV in the blood, help protect the immune system, and reduce the risk of HIV-related complications.
The three ingredients work as a team. Doravirine is a non-nucleoside reverse transcriptase inhibitor, often shortened to NNRTI. Lamivudine and tenofovir disoproxil fumarate are nucleoside/nucleotide reverse transcriptase inhibitors, often called NRTIs. All three target reverse transcriptase, an enzyme HIV needs to copy itself. The goal is to interrupt viral replication before HIV can make more trouble.
What Is Delstrigo Used For?
Delstrigo is approved as a complete regimen for HIV-1 infection in adults and pediatric patients who weigh at least 35 kg, or about 77 pounds. It may be prescribed for people who have never taken HIV medicines before, or it may be used to replace a current HIV regimen in people who are already virologically suppressed.
For someone switching to Delstrigo, healthcare providers look for several important conditions. The person should have an HIV-1 RNA level below 50 copies per mL on a stable antiretroviral regimen, no history of treatment failure, and no known resistance mutations to doravirine, lamivudine, or tenofovir. In other words, Delstrigo is not a random “let’s try this and see” medication. It is chosen after reviewing viral load, treatment history, resistance testing, kidney health, and other medications.
What Delstrigo Is Not Used For
Delstrigo is not approved to treat hepatitis B virus infection by itself, even though two of its ingredients, lamivudine and tenofovir disoproxil fumarate, have activity against HBV. Delstrigo is also not used as HIV pre-exposure prophylaxis, also known as PrEP. If someone needs HIV prevention medication rather than HIV treatment, they should discuss FDA-approved PrEP options with a healthcare provider.
Delstrigo Dosing: How to Take It
The recommended dose of Delstrigo is one tablet taken by mouth once daily. Each tablet contains doravirine 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg. It can be taken with or without food, which is excellent news for anyone whose breakfast schedule ranges from “balanced meal” to “coffee and hope.”
Try to take Delstrigo at the same time every day. Consistency helps keep drug levels steady and lowers the risk of missed doses. A phone alarm, medication app, calendar reminder, or pairing the dose with a daily routine can make adherence easier.
What If You Miss a Dose?
If you miss a dose of Delstrigo, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the next dose at your regular time. Do not take two doses at the same time. Doubling up does not “catch up” the right way; it only increases the chance of side effects.
Kidney Function and Dose Limits
Because Delstrigo is a fixed-dose combination tablet, the individual ingredients cannot be adjusted separately. It is not recommended for people with estimated creatinine clearance below 50 mL/min. Healthcare providers usually check kidney function before starting treatment and monitor it during therapy, especially in people with kidney disease risk factors.
What Does Delstrigo Look Like? Pictures and Tablet Identification
Delstrigo tablets are yellow, oval-shaped, film-coated tablets. One side is debossed with the corporate logo and the number “776,” while the other side is plain. This tablet description can help with medication identification, but it should not replace a pharmacist’s confirmation. If a pill looks different from usual, do not play detective with internet images alone. Call the pharmacy and verify it before taking it.
Common Side Effects of Delstrigo
The most common Delstrigo side effects include dizziness, nausea, and abnormal dreams. Some people may also experience headache, diarrhea, insomnia, vivid dreams, or tiredness. Many side effects are mild and may improve as the body adjusts, but persistent or bothersome symptoms should be discussed with a healthcare provider.
Abnormal dreams are one of the more memorable side effects. They may feel strange, vivid, or unusually cinematic. If your dreams suddenly have better production value than most streaming shows, mention it at your next appointmentespecially if sleep becomes difficult.
Side Effects That Need Medical Attention
Call a healthcare provider promptly if you notice symptoms such as decreased urination, swelling in the hands or feet, bone pain, muscle weakness, unusual tiredness, dark urine, yellowing of the skin or eyes, fever, swollen glands, or signs of a new infection. These symptoms may point to kidney problems, liver issues, immune system changes, or other concerns that should not be ignored.
Serious Warnings for Delstrigo
Hepatitis B Flare-Up Warning
Delstrigo carries an important warning about hepatitis B flare-ups after stopping treatment. If a person has both HIV-1 and hepatitis B, stopping medicines that contain lamivudine or tenofovir disoproxil fumarate can cause hepatitis B to worsen suddenly. Healthcare providers should test for hepatitis B before starting Delstrigo and monitor liver function closely for several months if Delstrigo is stopped.
Severe Skin Reactions and Allergic Reactions
Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported with Delstrigo. Get medical help right away for a painful rash, rash with blisters, peeling skin, mouth sores, red or swollen eyes, fever, facial swelling, trouble breathing, or signs of a serious allergic reaction.
Kidney Problems
Tenofovir disoproxil fumarate, one component of Delstrigo, has been associated with new or worsening kidney problems, including acute kidney failure and Fanconi syndrome, a type of kidney tubule injury. The risk may be higher when Delstrigo is taken with other medicines that can affect the kidneys, including high-dose or multiple nonsteroidal anti-inflammatory drugs such as ibuprofen or naproxen.
Bone Loss and Mineralization Problems
Tenofovir disoproxil fumarate can be associated with decreases in bone mineral density. Healthcare providers may consider bone health monitoring for people with osteoporosis risk factors, prior bone fractures, long-term steroid use, or kidney-related mineral problems. Report persistent bone pain, pain in the arms or legs, or muscle weakness.
Immune Reconstitution Syndrome
When HIV treatment starts working, the immune system may become stronger and begin reacting to infections that were previously hidden. This is called immune reconstitution syndrome. Symptoms may include fever, swollen lymph nodes, cough, weakness, or inflammation related to old infections. It sounds like the immune system finally clocked in and found an overflowing inboxbut it still needs medical attention.
Delstrigo Drug Interactions
Delstrigo has important drug interactions. Some medicines can lower doravirine levels so much that Delstrigo may stop working properly, raising the risk of HIV resistance. Delstrigo should not be taken with strong CYP3A enzyme inducers, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, enzalutamide, rifampin, rifapentine, mitotane, or St. John’s wort.
People should tell their healthcare provider and pharmacist about all prescription medicines, over-the-counter drugs, vitamins, herbal products, and supplements they take. St. John’s wort deserves special mention because it is “natural” in the same way poison ivy is natural: nature does not automatically mean safe.
Rifabutin and Delstrigo
If Delstrigo must be taken with rifabutin, the dosing plan changes. The usual recommendation is Delstrigo once daily plus an additional doravirine 100 mg tablet approximately 12 hours after the Delstrigo dose for as long as rifabutin is used. This adjustment should only be made under medical supervision.
Other HIV Medicines
Because Delstrigo is a complete HIV regimen, it generally should not be taken with other antiretroviral medicines for HIV-1 treatment unless a specialist specifically instructs otherwise. Taking overlapping HIV medications can increase side effects or duplicate ingredients.
Who Should Not Take Delstrigo?
Delstrigo should not be used by people who have had a previous hypersensitivity reaction to lamivudine. It should also be avoided with contraindicated interacting drugs such as certain seizure medicines, rifampin, rifapentine, enzalutamide, mitotane, and St. John’s wort. People with significant kidney impairment, especially estimated creatinine clearance below 50 mL/min, usually need a different regimen because the dose cannot be adjusted.
Delstrigo in Pregnancy and Breastfeeding
People who are pregnant, planning pregnancy, or could become pregnant should discuss Delstrigo with their healthcare provider. There is an antiretroviral pregnancy registry that collects information about outcomes after exposure to HIV medicines during pregnancy.
Breastfeeding guidance for people with HIV can depend on current public health recommendations, viral suppression, infant feeding options, and shared decision-making with a healthcare team. Delstrigo ingredients may pass into human milk, and potential risks include HIV transmission, viral resistance, and side effects in the infant. This is a conversation to have with an HIV clinician, not a quick guess made between diaper changes.
How Well Does Delstrigo Work?
Clinical studies have shown that Delstrigo can help many people achieve or maintain viral suppression when used appropriately. Viral suppression usually means the amount of HIV in the blood is very low, often below 50 copies per mL in clinical trials or below 200 copies per mL in many public health definitions. Keeping viral load suppressed helps protect immune health and greatly reduces the risk of transmitting HIV to others.
Effectiveness depends heavily on adherence. Skipping doses can allow HIV to multiply and may lead to resistance. Once resistance develops, future treatment options can become more complicated. That is why the best HIV medication is not only the one that looks good on paper, but the one a person can actually take consistently.
Practical Tips for Taking Delstrigo Safely
- Take Delstrigo once daily at the same time each day.
- Keep it in the original bottle with the desiccant to protect it from moisture.
- Do not store tablets loose in a pill box unless your pharmacist says it is appropriate.
- Tell your pharmacist before starting any new medicine or supplement.
- Do not stop Delstrigo without medical guidance, especially if you have hepatitis B.
- Keep lab appointments for viral load, kidney function, liver function, and other monitoring.
- Report rash, kidney symptoms, bone pain, severe fatigue, or signs of infection promptly.
Real-World Experiences and Daily Life With Delstrigo
Real-world experiences with Delstrigo often center on routine. For many people, the biggest win is simplicity: one pill, once a day, no required meal, and no booster. That can make HIV treatment feel less like a complicated medical project and more like brushing your teethimportant, daily, and best not skipped just because life got loud.
Some people prefer taking Delstrigo in the morning because it fits naturally with breakfast, coffee, or getting ready for work. Others prefer evening dosing because they are more likely to be home. The best time is the time that is easiest to repeat. A perfect dosing schedule that collapses after three days is less useful than a slightly boring routine that works for years.
A helpful strategy is to connect Delstrigo with an existing habit. For example, someone might take it after feeding the dog, before starting the coffee maker, or right after brushing their teeth. The brain loves patterns. It may forget a random pill at 2:37 p.m., but it tends to remember “pill after toothbrush” much better.
Side effect tracking can also make the experience smoother. If nausea appears, writing down when it happens, what was eaten, and how long it lasts can help the care team decide whether it is temporary, manageable, or related to something else. If dizziness occurs, patients should be careful with driving, stairs, or activities requiring alertness until they know how Delstrigo affects them.
Sleep-related effects, such as vivid dreams or abnormal dreams, are worth discussing honestly. Some people laugh them off; others find them disruptive. A clinician may suggest changing the dose time or evaluating other sleep factors. No one should feel silly bringing up dreams. In HIV care, “my sleep has turned into a sci-fi miniseries” is clinically relevant information.
Another common real-life issue is medication interaction anxiety. Because Delstrigo interacts with several drugs and supplements, patients may feel nervous about taking anything new. The solution is not panic; it is communication. Before adding a seizure medicine, antibiotic, herbal supplement, anti-inflammatory pain reliever, or over-the-counter product, check with a pharmacist or HIV provider. Pharmacists are basically interaction detectives with better lighting.
Travel requires planning. People taking Delstrigo should pack enough medication for the full trip plus extra in case of delays. It is smart to keep medication in carry-on luggage, not checked baggage. The original labeled bottle can help with airport security, emergency refills, and medication identification. Heat, humidity, and loose storage are not friends of this medication, so the original container matters.
Finally, Delstrigo works best as part of a bigger care plan. Viral load testing, kidney monitoring, liver checks, vaccination discussions, sexual health care, mental health support, and open conversations about adherence all matter. HIV treatment today can be highly effective, but it is still a partnership. The pill does important work; the care team, patient, pharmacist, and routine help make that work last.
Conclusion
Delstrigo is a complete, once-daily HIV-1 treatment that combines doravirine, lamivudine, and tenofovir disoproxil fumarate in one tablet. It can be a convenient option for eligible adults and pediatric patients weighing at least 35 kg, whether starting therapy for the first time or switching from a stable suppressive regimen. Its convenience is a major advantage, but it also comes with important warnings, especially around hepatitis B flare-ups, kidney health, bone effects, severe rash, and drug interactions.
The safest way to use Delstrigo is simple but serious: take it exactly as prescribed, avoid missed doses, check interactions before starting anything new, and keep regular lab appointments. HIV treatment is a long game, and Delstrigo is designed to help people play it with fewer pills in their pocket and more control over their health.
